Relay Therapeutics, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:RLAY) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Total assets 799.36 M728.84 M670 M621.33 M699.61 M967.46 M Total liabilities 78.28 M63.18 M62.29 M54.27 M57.43 M77.45 M Total equity 721.08 M665.66 M607.71 M567.06 M642.18 M890.01 M Total liabilities & shareholders' equities 799.36 M728.84 M670 M621.33 M699.61 M967.46 M Total debt —————— Net debt ——————

News

This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion

The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Beats Q1 Earnings Estimates

Relay Therapeutics: Revitalized By Breast Cancer Program, But Competition Is Intense

Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?

Celcuity: 'Buy' REVTORPYK FDA Approval First And sNDA Label Expansion Q3 2026 (CELC)

Biotech Is The Rate Cut Trade In Disguise

Absci: Eli Lilly Backs Alopecia Data With Funding, But Risks Remain (NASDAQ:ABSI)